ZAI Lab
- Revenue$144.3 MFY, 2021
- Market Capitalization$3.4 B2022-05-13
OverviewSuggest Edit
Zai Lab is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for cancer, autoimmune and infectious diseases. It offers Zejula, a selective small-molecule poly (ADP-ribose) PARP 1/2inhibitor; Optune, a portable device that delivers tumor treating fields; and Qinlock, a switch-control tyrosine kinase inhibitor.
| Type | Public | |
| Founded | 2014 | |
| HQ | Shanghai, CN | Map |
| Website | zailaboratory.com | |
| Employee Ratings |
Recent NewsAll News
- Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
- Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
- Zai Lab Plants a Tree for Every Employee on Earth Day 2022
- Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting
Key People/Management at ZAI Lab
Samantha Du
Founder, Chair and Chief Executive Officer
Harald Reinhart
Chief Medical Officer, Autoimmune and Infectious Diseases
Billy Cho
Chief Financial Officer
F. Ty Edmondson
Chief Legal Officer
William Liang
Chief Commercial Officer, President, Greater China
Tao Fu
Chief Strategy Officer
ZAI Lab Office Locations
ZAI Lab has offices in Shanghai, Beijing, Suzhou, Cambridge and in 3 other locations
Shanghai, CN (HQ)
4560 Jinke Road
Beijing, CN
22 Xidawang Road
Suzhou, CN
218 Sangtian Street
Hong Kong, HK
510 King's Road
Taipei, TW
Sec. 1, Keelung Road
Cambridge, MA, US
245 Main St 2nd floor
ZAI Lab Financials and Metrics
ZAI Lab Revenue
ZAI Lab's revenue was reported to be $144.31 m in FY, 2021
| USD | |
|---|---|
Revenue (FY, 2021) | 144.3m |
Gross profit (FY, 2021) | 99.9m |
Net income (FY, 2021) | (703.4m) |
EBITDA (FY, 2021) | (692.2m) |
EBIT (FY, 2021) | (704.2m) |
Market capitalization (13-May-2022) | 3.4b |
Closing stock price (13-May-2022) | 33.2 |
Cash (31-Dec-2021) | 964.1m |
EV | 2.4b |
ZAI Lab's current market capitalization is $3.4 b.
- Source: SEC Filings
Annual
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 129.0k | 13.0m | 49.0m | 144.3m |
Cost of goods sold | (44.0k) | (3.7m) | (12.1m) | (44.4m) |
Gross profit | 85.0k | 9.2m | 36.9m | 99.9m |
R&D expense | (118.6m) | (138.5m) | (222.7m) | (573.3m) |
Half Year
| USD | H1, 2020 |
|---|---|
Revenue | 19.2m |
Cost of goods sold | (5.0m) |
Gross profit | 14.2m |
R&D expense | (102.0m) |
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|
Revenue | 3.4m | 8.3m | 20.1m | 36.9m | 43.1m |
Cost of goods sold | (882.0k) | (2.2m) | (6.1m) | (9.3m) | (10.5m) |
Gross profit | 2.5m | 6.2m | 14.0m | 27.6m | 32.6m |
R&D expense | (58.9m) | (107.6m) | (203.9m) | (142.2m) | (55.1m) |
- Source: SEC Filings
Annual
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 63.0m | 75.9m | 442.1m | 964.1m |
Accounts Receivable | 89.0k | 3.8m | 5.2m | 47.5m |
Prepaid Expenses | 5.7m | 6.7m | 10.9m | 18.0m |
Inventories | 4.0k | 6.0m | 13.1m | 19.0m |
Half Year
| USD | H1, 2020 |
|---|---|
Cash | 258.6m |
Accounts Receivable | 7.0m |
Prepaid Expenses | 7.7m |
Inventories | 6.6m |
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|
Cash | 91.6m | 68.7m | 1.0b | 1.8b | 1.4b |
Accounts Receivable | 2.5m | 3.9m | 8.8m | 18.0m | 21.0m |
Prepaid Expenses | 6.0m | 4.2m | 14.3m | 12.9m | 17.1m |
Inventories | 141.0k | 890.0k | 12.6m | 11.1m | 12.5m |
- Source: SEC Filings
Annual
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | (139.1m) | (195.1m) | (268.9m) | (704.5m) |
Depreciation and Amortization | 1.6m | 3.8m | 4.6m | 6.5m |
Inventories | (4.0k) | (6.0m) | (7.2m) | (7.2m) |
Accounts Payable | 28.5m | (14.8m) | 40.0m | 63.5m |
Half Year
| USD | H1, 2020 |
|---|---|
Net Income | (128.6m) |
Depreciation and Amortization | 2.1m |
Inventories | (571.0k) |
Accounts Payable | 9.7m |
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|
Net Income | (148.6m) | (232.9m) | (396.2m) | (492.6m) | |
Depreciation and Amortization | 2.5m | 1.4m | 3.0m | 4.6m | |
Inventories | 502.0k | 1.7m | 248.0k | ||
Accounts Payable | (21.2m) | 63.0m | (11.2m) |
- Source: SEC Filings
ZAI Lab Revenue Breakdown
ZAI Lab revenue breakdown by business segment: 64.9% from ZEJULA, 27.0% from OPTUNE, 8.1% from QINLOCK and 0.0% from Other
ZAI Lab Cybersecurity Score
ZAI Lab Environment, Social & Governance (ESG) Ratings
ZAI Lab Online and Social Media Presence
ZAI Lab's Trends
ZAI Lab News and Updates
April 28, 2022
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision o…
April 21, 2022
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
Zai Lab’s engagement of an audit firm located in the United States is expected to facilitate the Company’s continued listing on Nasdaq because KPMG is subject to inspection by the PCAOB Zai Lab’s engagement of an audit firm located in the United States is expected to facilitate the Company’s continu…
April 19, 2022
Zai Lab Plants a Tree for Every Employee on Earth Day 2022
Partners with One Tree Planted and Donates at least $25,000 Partners with One Tree Planted and Donates at least $25,000
April 06, 2022
Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting
- First preview of preclinical data for ZL-1218, an anti-CCR8 antibody, in an oral presentation
April 05, 2022
ZLAB EQUITY NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading b…
March 31, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
ZAI Lab Frequently Asked Questions
When was ZAI Lab founded?
ZAI Lab was founded in 2014.
Who are ZAI Lab key executives?
ZAI Lab's key executives are Samantha Du, Harald Reinhart and Billy Cho.
How many employees does ZAI Lab have?
ZAI Lab has 1,194 employees.
What is ZAI Lab revenue?
Latest ZAI Lab annual revenue is $144.3 m.
What is ZAI Lab revenue per employee?
Latest ZAI Lab revenue per employee is $120.9 k.
Who are ZAI Lab competitors?
Competitors of ZAI Lab include Amoy Diagnostics, BGI Genomics and Berry Genomics.
Where is ZAI Lab headquarters?
ZAI Lab headquarters is located at 4560 Jinke Road, Shanghai.
Where are ZAI Lab offices?
ZAI Lab has offices in Shanghai, Beijing, Suzhou, Cambridge and in 3 other locations.
How many offices does ZAI Lab have?
ZAI Lab has 7 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies